Bruker BioSpin

bruker.com

The world’s most comprehensive range of magnetic resonance and preclinical imaging instrumentation available under one brand - a brand synonymous with excellence, innovation and quality. Bruker is offering a wide range of applications for molecular characterization in chemistry and life sciences as well as solutions for materials and preclinical research. The Bruker BioSpin business group includes NMR, EPR, compact and Time-Domain (TD) NMR, preclinical MRI, optical imaging, microCT, and PET/SPECT/CT.a

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

OMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCESOMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCES

OMass Therapeutics | February 21, 2022

news image

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Read More

CELL AND GENE THERAPY

CTA APPROVAL OF BIOINVENT'S BI-1808, A FIRST-IN-CLASS ANTI-TNFR2 ANTIBODY, SETS STAGE FOR PHASE I/IIA TRIAL

BioInvent | October 27, 2020

news image

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has received regulatory authority approval of its clinical trial application (CTA) in Denmark for a Phase I/IIa, first-in-human study of BI-1808, as monotherapy and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL)...

Read More

DOLCAS BIOTECH COMMITS TO ACCELERATING CLEAN-LABEL NUTRACEUTICALS FROM UPCYCLED RAW MATERIALS

PR Newswire | July 24, 2020

news image

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

Read More

INDUSTRIAL IMPACT

LARONDE ATTRACTS $440M IN FIRST EXTERNAL FINANCING TO FURTHER ADVANCE ENDLESS RNA™ PLATFORM

Laronde | August 30, 2021

news image

Laronde, the company pioneering Endless RNA™ a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, today announced that it has raised $440 Million in a Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc.,...

Read More
news image

INDUSTRIAL IMPACT

OMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCESOMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCES

OMass Therapeutics | February 21, 2022

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Read More
news image

CELL AND GENE THERAPY

CTA APPROVAL OF BIOINVENT'S BI-1808, A FIRST-IN-CLASS ANTI-TNFR2 ANTIBODY, SETS STAGE FOR PHASE I/IIA TRIAL

BioInvent | October 27, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has received regulatory authority approval of its clinical trial application (CTA) in Denmark for a Phase I/IIa, first-in-human study of BI-1808, as monotherapy and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL)...

Read More
news image

DOLCAS BIOTECH COMMITS TO ACCELERATING CLEAN-LABEL NUTRACEUTICALS FROM UPCYCLED RAW MATERIALS

PR Newswire | July 24, 2020

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

Read More
news image

INDUSTRIAL IMPACT

LARONDE ATTRACTS $440M IN FIRST EXTERNAL FINANCING TO FURTHER ADVANCE ENDLESS RNA™ PLATFORM

Laronde | August 30, 2021

Laronde, the company pioneering Endless RNA™ a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, today announced that it has raised $440 Million in a Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc.,...

Read More